KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Capital Expenditures (2018 - 2025)

Moderna (MRNA) has disclosed Capital Expenditures for 8 consecutive years, with $39.0 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 92.53% to $39.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $192.0 million through Dec 2025, down 81.73% year-over-year, with the annual reading at $192.0 million for FY2025, 81.73% down from the prior year.
  • Capital Expenditures for Q4 2025 was $39.0 million at Moderna, down from $106.0 million in the prior quarter.
  • The five-year high for Capital Expenditures was $522.0 million in Q4 2024, with the low at -$199.0 million in Q3 2023.
  • Average Capital Expenditures over 5 years is $94.2 million, with a median of $47.5 million recorded in 2021.
  • The sharpest move saw Capital Expenditures surged 25800.0% in 2022, then plummeted 176.83% in 2023.
  • Over 5 years, Capital Expenditures stood at $45.0 million in 2021, then soared by 104.44% to $92.0 million in 2022, then tumbled by 119.57% to -$18.0 million in 2023, then soared by 3000.0% to $522.0 million in 2024, then tumbled by 92.53% to $39.0 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $39.0 million, $106.0 million, and -$3.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.